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AbstratHow do the normal prion protein (PrPC) and infetious prion protein (PrPS) pop-ulations interat in an infeted host? To answer this question, we analyze the behaviorof the two populations by studying a system of dierential equations. The systemis onstruted under the assumption that PrPS proliferates using the mehanism ofnuleated polymerization. We prove that with parameter input onsistent with ex-perimentally determined values, we obtain the persistene of PrPS. We also proveloal stability results for the disease steady state, and a global stability result for thedisease free steady state. Finally, we give numerial simulations, whih are onrmedby experimental data.Keywords: Prion diseases; Prion proliferation; Solution persistene; Nuleated polymer-ization mehanismBates College, Department of Mathematis, 213 Hathorn Hall Bates College, Lewiston, Maine 04240USA, mgreerbates.eduyInstitut Camille Jordan, Universite Claude Bernard Lyon 1, 43 boulevard du 11 Novembre 1918, 69622Villeurbanne edex, Frane, pujomath.univ-lyon1.frzCorresponding author. Vanderbilt University, Department of Mathematis, 1326 Stevenson Center,Nashville, TN 37240-0001, USA, glenn.f.webbvanderbilt.edu1
1 IntrodutionThough widely investigated, the pathogenesis of transmissible spongiform enephalopathies(TSEs) remains inompletely understood. These diseases, members of the fatal neurode-generative disease family, have dierent names depending on the mammalian speies. Theyare alled srapie for sheep or bovine spongiform enephalopathy (BSE) for attle, and forhumans they appear under forms alled kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Sheinker syndrome and fatal familial insomnia. It is believed that they showommon pathologies suh as spongiform degeneration, desribed as large vauoles in theortex and the erebellum (Horwih and Weissman, 1997). They are also haraterized bylong inubation periods, a lak of immune response and invisibility to detetion as viruses.It has been shown that only one infetious agent is the ause of these diseases (GriÆth, 1967;Prusiner, 1982). This agent is the prion; its disovery was very surprising in the sense thatit is thought not to be a virus or any other viroid-like agent but is ommonly aepted tobe a protein (Aguzzi and Polymenidou, 2004; Prusiner, 1991). The fat that a protein alonean transmit an infetious disease has been a great ontroversy within the sienti om-munity. However, despite some arguments against this protein-only hypothesis, the prion isnow widely regarded as the best explanation for TSEs.Muh progress was made in the 1980's in understanding strutural aspets of the dierentforms of prion protein (Oesh et al., 1985; Prusiner, 1991; Prusiner et al., 1981; Prusineret al., 1984). To summarize, we an say that the prion infetious agent is a modied formof a normal protein alled PrPC (Prion Protein Cellular) whih is a normal proteinase K-sensitive form of prion protein PrP. Single moleules of the protein PrPC , whih we willrefer to as monomers, an normally be found in the human system. Many authors haveinvestigated the funtional role of prions (Bounhar et al., 2001; Brandner et al., 1996; Brownet al, 2002; Chiesa et al., 2005; Kim et al., 2004; Li and Harris, 2005; Rouou et al., 2003;2
Rouou et al., 2004). Brandner et al. (1996) showed that PrPS does not diretly damageneurons. Rouou et al. (2003, 2004) showed that for human neurons, normal PrP loated inthe ytosol retains its protetive funtion against Bax, a substane in the human ell whihwhen ativated provokes ell apoptosis. In other words, normal PrP ould be onsidereda natural protetion against apoptosis. Without it, a massive destrution of our neuronswould our under stress.On the other hand, the infetious protein PrPS (Prion Protein Srapie) is an abnormalpathogeni onformation of PrPC and is the origin of the TSEs. PrPS is hydrophobi andhas a tendeny to form aggregates (Prusiner, 1998). It is then more stable than PrPC andmuh more resistant to proteolyti treatment as well as radiation and high temperatures(Huang et al., 1984; Pan et al., 1993). The motivation to study the dynamis of theseprotein populations omes from the researh of Rouou et al. (2003) and the authors quotedabove, whih suggests that the PrPS proteins do not diretly damage the neurons in theTSEs. Indeed, if we assume that PrPS is an aggregate that onverts PrPC monomers as itrepliates, then the neurons would be damaged beause the protetion of PrPC disappearsand no shield against the Bax within the ell persists. Thus, the more an animal or human isstressed the faster the neurons die (Brown et al., 2002). Obviously, this biologial assumptionis very simplied here, and there exist other hypotheses regarding the ause of death due tothe prion disease.The objetive in this work is to understand the dynamis of the PrPC and PrPS popu-lations. Our goal is to develop a basi model inorporating the essential elements of priondisease. We would like to understand under what onditions the PrPS population surviveswhile the monomer PrPC population delines, and if suh onditions are biologially realisti.In other words, we want to study the stability of the protein populations involved in thesediseases. In order to study this behavior we need to onsider a suÆiently robust model.Several models to explain the repliation proess of PrPS have been proposed (Cohen et al.,3
1994; Eigen, 1996; Harper and Lansbury, 1997; Jarrett and Lansbury, 1993; Kulkarni et al.,2003; Laurent, 1997; Masel et al., 1999; Mobley et al., 2003; Nowak et al., 1998; Poshel etal., 2003; Slepoy et al., 2001). These models are distinguished primarily as one-dimensional(lengthening brils) or two-dimensional (planar aggregates). Areal aggregation models (thatis, two-dimensional aggregations on regular arrays orresponding to ell surfaes) have beeninvestigated (Kulkarni et al., 2003; Mobley et al., 2003; Slepoy et al., 2001) and experimen-tal evidene of areal aggregation has been shown (Govaerts et al., 2004; Wille et al., 2002).There is experimental evidene that PrP proteins with glyo-phospho-inositol (GPI) anhorsdeleted an yield inreased srapies upon inoulation without disease symptoms (Chesebroet al., 2005). Areal aggregation models have provided an impressive theoretial explanationof the highly reproduible logarithmi orrelation of inubation times and inoulum doses,as well as experimentally observed deviations in this relationship at small doses (Kulkarniet al., 2003).The view that PrPS aggregates are essentially one-dimensional brilli strutures length-ening in both linear diretions has been investigated (Jarrett and Lansbury, 1993; Collins etal., 2004; Lansbury and Caughey, 1981; Sheibel et al., 2001). Collins et al. (2004) investi-gate one-dimensional yeast prion aggregation by single moleule uoresene measurements,whih indiate that brils grow by monomer addition. The one-dimensional propagationof prion brils has been modeled mathematially (Masel et al., 1999; Nowak et al. 1998;Poshel et al., 2003). Masel et al. (1999) hypothesize nuleated polymerization (see Figure1) as the primary mehanism of PrPS proliferation and develop a deterministi model forit onsisting of an innite system of ordinary dierential equations, one for eah possiblebril length. The model in Masel et al. (1999) is the starting point of our investigation, butwe onsider a ontinuum of possible bril lengths desribed by partial dierential equations(Greer, 2002). The advantages of our modeling approah are that it is oneptually moreaessible and mathematially more tratable.4
We state our model of prion proliferation, then nd the steady state values of the system.We study the loal stability of the disease free and disease steady states. We prove global sta-bility for the disease free steady state and the onditions neessary for persistene of the dis-ease. We onlude with numerial simulations based on experimental data (Masel et al., 1999;Rubenstein et al., 1991). All proofs of our propositions onerning the existene, uniqueness,and asymptoti behavior of the solutions of the model are available either on request or at thefollowing internet address: http://www.math.vanderbilt.edu/%7Epujo/My%20Researh/ sup-plementarymaterial.htm2 The model of prion proliferationOur model desribes nuleated polymerization, the mehanism by whih prions are hypoth-esized to repliate (Nowak et al., 1998). It is neessarily abstrat, beause it desribes anextremely omplex biologial proess. The model ontains six basi parameters, eah ofwhih has a fundamental biologial interpretation. The nuleated polymerization theoryonsiders the PrPS protein to be a polymeri form of PrPC . It is important to point outthat above a ritial size, PrPS is very stable and does not polymerize anymore (Pan et al.,1993). Only terminally trunated forms of the PrPS polymerize. Our work is onsequentlyfoused on these trunated forms that polymerize whih by language abuse we name PrPS.By polymerizing, we mean that PrPS inreases its length by attahing to its end units ofonverted PrPC in a stringlike formation (Sheibel et al., 2001). After a PrPS polymerattahes to a PrPC monomer, the PrPC is onverted to the infetious PrPS form. It isassumed that the PrPS proteins are long enough to wrap into a helial shape, in whih theyform stabilizing bonds (Wille et al., 2002). The rst winding of the helix, ahieved at theritial size, is the \nuleus" referred to by the term nuleated polymerization (see Fig. 1)(Masel et al., 1999). 5
The bonds formed in a PrPS polymer likely onfer PrPS greater metaboli stability thanPrPC (Masel et al., 1999). This dierene in stability is manifested in the parameters formetaboli degradation of PrPS and PrPC . Polymers of PrPS an split into smaller polymers,and the mehanisms of lengthening and splitting are the basis of prion proliferation (see Fig.1). A split usually transforms one infetious polymer into two smaller infetious polymers,eah of whih an attah PrPC . However, when a newly split polymer falls below the ritialsize, it immediately degrades into PrPC monomers. We note that our assumption that thePrPS polymers an degrade into PrPC units is ontroversial, although there is experimentalevidene that monomers less than a minimum size are energetially unfavorable (Poshelet al., 2003; Wille et al., 2002). All our results, however, are valid with or without thisassumption, that is, our minimum viable polymer length may be as small as 1.2.1 The monomer populationLet us denote by V (t) the population of PrPC monomers at time t > 0, and by U(t) =R1x0 u(x; t)dx the total population of polymers of length x greater than a minimum lengthx0 > 0. The funtion u is the density of polymers at time t > 0 with respet to thelength x 2 (x0;1). Note that polymer lengths have been shown to range over thousands ofmonomer units (Masel et al., 1999; Prusiner, 1986). In (Masel et al., 1999) polymer lengthsx were assumed to be integer values, but we assume ontinuous values for mathematialtratability. The monomer population satises the ordinary dierential equationdV (t)dt =   V (t)  V (t)U(t) + 2 Z x00 x Z 1x0 (y)(x; y)u(y; t)dydx (1)where  > 0 is the onstant bakground soure of monomers,  > 0 is the onstant metabolidegradation rate of monomers and  is the polymerization rate, i.e. the rate at whihpolymers attah to, and onvert, monomers. In the last term of the right hand side, (y) gives6
the possibly length-dependent likelihood of splitting of polymers to monomers. Supposinga split ours, (x; y) is the probability of an polymer of length y splitting to any shorterlength x with the other piee having length y   x, and is dened in the following way:(x; y) = 8><>: 0; if y  x0 or y  x;1=y; if y > x0 and 0 < x < y: (2)The form of Eq. (2) means that the probability a length y splits to any shorter length x isequally likely. Observe that for a xed value of y,Z 10 (x; y)dx = 8><>: 0; if y  x0;1; if y > x0: (3)In Eq. (1), the V (t)U(t) term on the right-hand side represents the loss of monomers asPrPC units are attahed to the polymer PrPS. The term 2 R x00 x R1x0 (y)(x; y)u(y; t)dydxrepresents the monomers gained when a PrPS polymer splits with at least one polymershorter than the minimum length x0. We assume that suh a polymer piee degrades imme-diately into PrPC units. We also give the initial onditionV (0) = V0; (4)where V0 is positive.
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2.2 The polymer populationThe polymer population is desribed by the following transport equation,tu(x; t) + V (t) xu(x; t) =  (x)u(x; t)  (x)u(x; t)+2 Z 1x (y)(x; y)u(y; t)dy: (5)While the term V (t)U(t) of Eq. (1) represents the loss of PrPC monomers as they arepolymerized, the term V (t) xu(x; t) in Eq. (5) shows the gain in length of PrPS dueto polymerization. The rst term on the right hand side of Eq. (5) gives the metabolidegradation of PrPS. In this paper, for simpliity we assume polymers are equally likely tosplit anywhere along their length where two protein units join, hene (x) = x. We alsoassume (x)  . Note the important roles of  and . In our model there is a very smallprobability that PrPS polymers an grow to greater lengths than have been experimentallyobserved. Careful hoies of both  and  an render this probability negligible. Thesehoies do not ontradit the biologial observations and without them, the study of themodel ould beome extremely omplex. The last two terms of Eq. (5) desribe splitting.The term (x)u(x; t) is the loss of polymers, subjet to the splitting rate (x). The lastterm of the right hand side is the ount of all the polymers of length x resulting from thesplitting of polymers of length greater than x . We give the initial ondition for the polymerpopulation as u(x; 0) = '(x); for x0 < x <1; (6)and the boundary ondition to beu(x0; t) = 0; for t  0: (7)8
3 An assoiated system of ordinary dierential equa-tionsFrom the system omprised of Eq. (1) and Eqs. (4-7), a straightforward omputation allowsus to dedue the following assoiated system of ordinary dierential equations8>>>>>>>>>><>>>>>>>>>>:
ddtU(t) = P (t)  U(t)  2x0U(t);ddtV (t) =   V (t)  V (t)U(t) + x20U(t);ddtP (t) = V (t)U(t)  P (t)  x20U(t); (8)where P (t) = R1x0 xu(x; t)dx is the total population of PrPS monomers omprising thepolymers at time t. We remark that System 8 is analogous to the system of three dierentialequations presented by Masel et al. (1999). However, in our work, we analyze dierentaspets of the system. Further, System 8 is obtained from Eq. (1) and Eqs. (4-7), whih isa formulation of the model based on ontinuous bril lengths. The System Eq. (1) and Eqs.(4-7) arries more biologial information, namely the distribution of prion brils, as well asthe lengthening and splitting proesses.There are two steady states for System (8): the disease free steady stateU = 0; V = = and P = 0;and the prion disease steady stateU =    (x0 + )2(2x0 + ) ; V = (x0 + )2 and P =    (x0 + )2 :9
Note that the disease steady state exists only if x0 +  < (  =)1=2. The left-handside of this inequality is related to the net loss of PrPS polymers due to their degradationand splitting to unstable lengths, and the right-hand side is related to the net produtionof polymers due to their lengthening and splitting to stable lengths as they onsume theavailable supply of PrPC , in other words, the inequality onditioning the disease steadystate an be interpreted in terms of the degradation, splitting and lengthening rates ofthe polymers. We state below results onerning the existene, uniqueness and the partialdierential equations Systems Eq. (1) Eqs. (4-7). We also state results onerning thestability of the steady state of these two systems. The proofs of Propositions 3.0.1 (i) and(ii) are available in the Appendix. The proof of Proposition 3.0.1 (iii) is given in Pruss etal. (2006). The proof of Proposition 3.0.2 is based on the results for the assoiated systemof ordinary dierential equations and is given in Engler et al. (2006).Proposition 3.0.1 Let , ,  , , , x0 > 0. Let X = f(U; V; P ) 2 R3+ : U  0; V  0 andP  x0Ug(i) For eah (U(0); V (0); P (0)) 2 X there is a unique solution (U(t); V (t); P (t)) to theinitial value problem (8) for t  0. Further, (U(t); V (t); P (t)) 2 X for t  0.(ii) The disease free steady state given by (U; V ; P ) = (0; =; 0) is globally stable in X forthe system (8) (that is, limt!1(U(t); V (t); P (t)) = (U; V ; P ) for all (U(0); V (0); P (0)) 2 X,if (=)1=2 < x0 + (iii) The disease steady state given byU =    (x0 + )2(2x0 + ) ; V = (x0 + )2 and P =    (x0 + )2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is globally stable in X for the system (8), if(=)1=2 > x0 + Proposition 3.0.2 Let , ,  , , , x0 > 0. Let X = R  L1((x0;1); xdx). For eah(V0; ) 2 X+ there is a unique solution (V (t); u(:; t)) to the initial value problem System Eq.(1) and Eqs. (4-7) for t  0 and (V (t); U(t); P (t)) 2 X+. The disease free steady state(=; 0) is globally stable in X+, if(=)1=2 < x0 + :The disease steady stateV = (x0 + )2 ; u(x) = 2(   (+ x0)2)( + x0)(+ 2x0)((x  x0)+ x0 );where (r) = (r + r2=2)exp( (r + r2=2)), is globally stable in X+, if(=)1=2 > x0 + :4 Numerial IllustrationsOur model an be used for simulations based on experimental data for prion proliferation.The model has six parameters: x0; ; ; ; , and  . The minimum stable polymer lengthx0 is estimated as 6 to 30 in Masel et al. (1999), but remains ontroversial (Masel et al.,2005). The half-life of PrPC monomers is estimated as 3   6 hr from studies for mouseneuroblastoma ells (Borhelt et al., 1990; Caughey et al., 1989) whih means   3   5day 1. We estimate the PrPC soure as   103   104, whih is onsistent with the values11
in Masel et al. (1999). These three parameters x0; ;  are obtainable independently of thedisease dynamis. We note that the pre-inoulation steady state V (0) = = relates  and independently of the disease dynamis. The other three parameters ; ;  an be obtainedexperimentally from the observed disease steady state valuesV = (x0 + )2U =    (x0 + )2(2x0 + )P=U = 2x0 + whih are, respetively, the monomer population, the polymer population, and the meanpolymer length at disease steady state. These three equations yield a unique solution for; , and  in terms of x0, , , U , V and P given by =  (P   Ux0)2(V    )P U V (P   2Ux0) ;  =  V  + P and  = U( V  + )P (P   2Ux0) :We apply our model to experimental data in Rubenstein et al. (1991). The parametervalues for the simulation are given in Table 1. MATHEMATICA ode used in the simulationsis available on request.4.1 Convergene of the density u(x; t) to the disease steady stateIn Fig. 2, the early (left panel) and late (right panel) stages for the pathogenesis of prionproliferation are given for the polymer density u(x; t). It an be seen in Fig. 2 and alsoin Fig. 3 that the mean polymer length rst inreases and then dereases as it stabilizesover disease progression. Our model explains this phenomenon as follows. In the early stagethere is an abundane of PrPC monomers whih are maintained at a onstant soure rate. As12
this population is onsumed by the lengthening and splitting polymers, the mean polymerlength is onstrained. This is onsistent with the hypothesis formulated by Rouou et al.(2003), that is, deaths attributable to prion disease result from the pathogeni onsumptionof normal PrPC monomers. Both simulations assume an initial PrPC population V0 = 880and an initial PrPS population u(y; 0) given by .000002 times a Gaussian distribution withmean .15 and standard deviation .03.4.2 Analysis of infetivityIn Fig. 4 we show the dependene of the inubation time on the inoulation dose. It iswell doumented (Prusiner, 1986; Ferreira et al., 2003) that the inubation time (dened asappearane of disease symptoms or death) is a log funtion of the inoulum dose. In the toppanel of Fig. 4 the inubation time in days is graphed for nine order of magnitude dilutions ofthe inoulum dose U(0). In the bottom panel of Fig. 4 the orresponding graphs of U(t) aregiven. The inubation time is dened as the number of days for U(t) to reah 130 SAF=sqwhih is the experimental value obtained in Rubenstein et al. (1991) for the appearane ofsymptoms in mie injeted intraerebrally with 139A srapie strain as measured in spleen.In Fig. 5 we graph the solution of System (8) for an inoulum dose orresponding to datain Rubenstein et al. (1991). The model simulation ts the data for the disease progression.This data has also been simulated by Poshel et al. (2003) who used a model similar toMasel et al. (1999). In (Rubenstein et al., 1991) the authors used srapie-assoiated brils(SAF) as the indiator of infetivity. In their experiment, they infeted mie by intraerebralinjetion as well as intraperitoneal injetion then measured the level of SAF in the brain andspleen at various times after inoulation. The data they obtained are shown in Fig. 5 (dotsin the graph of the right part, the arrow represents the onset of linial disease). Here weshow the data from the spleen after an intraerebral injetion (Fig. 2 in (Rubenstein et al.,13
1991)).5 ConlusionWe have presented a model of prion proliferation with biologial assumptions similar to thoseof Masel et al (1999). Our model diers from theirs in that we onsider prion polymer lengthto be a ontinuous rather than disrete struture variable. This hange from a disrete modelallows us to show dierent behaviors of the interating protein populations. As one example,our model shows the omplete polymer distribution u(x; t) for eah time t.The ontinuous model is simple enough to provide lear numerial results and be easilymanipulated, and it is detailed enough to desribe many aspets of prion diseases. It isaurate and onsistent when ompared to biologial data. We an use the model to preditevents, suh as the early inrease and later derease in mean polymer length (Fig. 3), thelog relationship between inoulation doses and inubation times (Fig. 4) and the saturationof total PrPS mass as a determinant of onset of linial symptoms (Fig. 5). Yet the modelis mathematially hallenging enough to leave open questions for both mathematiians andexperimental biologists. These inlude global stability of the disease steady state and a moreomplete desription of PrP lengths and quantities in vivo.We have several diretions for future work. The model requires analysis in the ase when and  are not onstant and investigation of unstable behavior and possible osillations.We will study eah parameter in more depth to better understand its inuene on diseaseprogression. And nally, the model may be adapted to reet further biologial understand-ing of polymer formation.
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A Proof of Proposition 3.0.1(i)We rst give the following equivalent system of equations to system (8) in terms of U(t); V (t);W (t);where W (t) = P (t)  x0U(t):8>>>>>>>>>><>>>>>>>>>>:
ddtU(t) = W (t)  (+ x0)U(t);ddtV (t) =   V (t)  V (t)U(t) + x20U(t);ddtW (t) = V (t)U(t)  (+ x0)W (t):We re-write the new system in vetor form asddtZ(t) = AZ(t) + F (Z(t)); Z(0) = (U(0); V (0);W (0)); (9)where Z(t) = (U(t); V (t);W (t))T , A is the matrix dened by
A = 0BBBB  (+ x0) 0 x20   00 0  (+ x0)
1CCCCAand F (Z(t)) = (0;   U(t)V (t); U(t)V (t))T . The integration of Equation (9) givesZ(t) = etAZ(0) + Z t0 e(t s)AF (Z(s))ds (10)where
15
etA = 0BBBB e t(+x0) 0 e t(+x0)te t(1 e t(+x0 ))x20+x0  e t e t(+x0)x202(et(+x0 ) 1 t(+x0 ))(+x0 )20 0 e t(+x0)
1CCCCAif + x0 6= , and etA = 0BBBB e t 0 e tte ttx20 e t 12e tt2x2020 0 e t
1CCCCAif  + x0 = . Then, etA(R3+)  R3+ for t  0, F is Lipshitz ontinuous on bounded setsin R3+ , and for eah Z 2 R3+ , Z + hF (Z) 2 R3+ for h > 0 and suÆiently small. Thus, thereexists a unique solution of (9) in R3+ for eah Z(0) 2 R3+ dened on a maximal interval ofexistene [0; tmax), and either tmax =1 or tmax < 1 and lim t! t+maxkZ(t)k =1 (Martin(1976)). Sineddt(U(t) + V (t) +W (t)) = W (t)  (+ x0)(U(t) +W (t)) +   V (t) + x20U(t) + (U(t) + V (t) +W (t))for some positive onstant , the solution Z(t) stays bounded on bounded intervals of t.Thus, tmax =1, and the existene of a unique global positive solution is proved.B Proof of Proposition 3.0.1(ii)Let us dene the mapping F : C(R3+)  ! R byF (U; V; P ) = (V    )2 + bU + b P;
16
with b = 12  2(4x0+ 22 + (x20   )) :Then F is a Liapunov funtional. Indeed, notie rst that the ondition (=)1=2 < x0+implies that b > 0, and thus (0; =; 0) is a strit minimum for F. It is not diÆult to showthat _F (U; V; P ) =  2bUx0   b Ux20 + 2UV x20   2V 2 + 4V 
 2Ux20   22   bU + b UV    2UV 2 + 2UV 
and then, _F (U; V; P )   U b(2x0 + ) + (b  + 2( V  + ))(x20   V ) ;whih for b given above and from the ondition (=)1=2 < x0 + , leads to_F (U; V; P )  0:Then from Hale (1969) the proof is omplete.ReferenesBorhelt, D. R., Sott, M., Taraboulos, A., Stahl, N., Prusiner, S. B., 1990. Srapie andellular prion proteins dier in their kinetis of synthesis and topology in ultured ells. J.17
Cell Biol. 110, 743-752.Bounhar, Y., Zhang, Y., Goodyer, C., LeBlan, A., 2001. Prion protein protets humanneurons against bax-mediated apoptosis. J. Biol. Chem. 276:39145-39149. 4. Aguzzi, A.,and M. Polymenidou. 2004. Mammalian prion biology: one entury of evolving onepts.Cell. 116, 313-327.Brandner, S., Isenmann, S., Raeber, A., Fisher, M., Sailer, A., Kobayashi, Y., Marino, S.,Weissmann, C., Aguzzi, A., 1996. Normal host prion protein neessary for srapie-induedneurotoxiity. Nature. 379, 339-343.Brown, D., Niholas, R., Canevari L., 2002. Lak of prion protein expression results in aneuronal phenotype sensitive to stress. J. of Neurosiene Researh. 67, 211-224.Caughey, B., Rae, R. E., Ernst, D., Buhmeier, M. J., Chesebro, B., 1989. Prion proteinbiosynthesis in srapie-infeted and uninfeted neuroblastoma ells. J. Virol. 63, 175-181.Chesebro, B., Trilo, M., Rae, R., Meade-White, K., Teng, C., LaCasse, R., Raymond, L.,Favara, C., Baron, G., Priola, S., Caughey, B., Masliah, E., Oldstone, M., 2005. Anhorlessprion protein results in infetious amyloid disease without linial srapie. Siene. 308,1435-1439.Chiesa, R., Piardo, P., Dossena, S., Nowoslawski, L., Roth, K. A., Ghetti, B., Harris, D.A., 2005. Bax deletion prevents neuronal loss but not neurologial symptoms in a transgenimodel of inherited prion disease. Pro. Natl. Aad. Si. USA. 102, 238-243.18
Cohen, F. E., Huang, Z., Fletterik, R. J., Baldwin, M., Prusiner, S. B., 1994. Struturallues to prion repliation. Siene. 264, 530-531.Collins, S., Douglass, A., Vale, R., Weissman, J., 2004. Mehnism of prion propagation:Amyloid growth ours by monomer addition. PLOSBio. 2, 1582-1590.Eigen, M. 1996. Prionis or the kineti basis of prion diseases. Biophys. Chem. 63, 11-18.Engler, H., Pruss, J., and Webb, G. F. ,2006. Analysis of a Model for the Dynamis ofPrions II. In press.Ferreira, A. S., da Silva, M. A., Cressoni, J. C., 2003. Stohasti modeling approah to theinubation time of prioni diseases. Phys. Rev. Lett. 90, 198101-198104.Govaerts, C., Wille, H., Prusiner, S. B., Cohen, F. E., 2004. Evidene for assembly of prionswith left-handed -helies into trimers. Pro. Natl. Aad. Si. 101, 8342-8347.Greer, M. L., 2002. A population model of prion dynamis. Ph. D. Thesis, VanderbiltUniversity.GriÆth, J. S., 1967. Nature of the srapie agent. Nature. 215, 1043-1044.Hale, J., 1969. Ordinary Dierential Equations. Wiley-Intersiene, New-York.Hale, J., 1977. Theory of Funtional Dierential Equations. Springer, Berlin.19
Harper, J. D., Lansbury, P. T., 1997. Models of amyloid seeding in Alzheimer's disease andsrapie: Mehanisti truths and physiologial onsequenes of the time-dependent solubilityof amyloid proteins. Annual Review of Biohemistry. 66, 385-407.Horwih, A. L., Weissman, J. S. , 1997. Deadly onformations: protein misfolding in priondisease. Cell. 89:499-510. 3. Prusiner, S. B. 1982. Novel proteinaeous infetious partilesause srapie. Siene. 216, 136-144.Huang, Z. W., Gabriel, J. M., Baldwin, M. A., Fletterik, R. J., Prusiner, S. B., Cohen, F.E, 1984. Proposed three-dimensional struture for the ellular prion protein. Pro. Natl.Aad. Si. USA. 47, 71-79.Jarrett, J. T., Lansbury, P. T., 1993. Seeding \one-dimensional rystallization" of smyloid:a pathogeni mehanism in Alzheimer's disease and srapie? Cell. 73, 1055-1058.Kim, B. H., Lee, H. G., Choi, J. K., Kim, J. I., Choi, E. K., Carp, R. I., Kim, Y. S., 2004.The ellular prion protein (prp) prevents apoptoti neuronal ell death and mitohondrialdysfuntion indued by serum deprivation. Moleular Brain Researh. 124, 40-50.Kulkarni, R. V., Slepoy, A., Singh, R. R. P., Cox, D. L., Pazmandi, F., 2003. Theoretialmodeling of prion disease inubation. Biophys. J. 85, 707-718.Lansbury, P., Caughey, B., 1981. The hemistry of srapie infetion: impliation of the \ie9" metaphor. Chem. Biol. 2, 1-5.Laurent, M. 1997. Autoatalyti proesses in ooperative mehanisms of prion diseases.20
FEBS Lett. 407, 1-6.Li, A., Harris, D. A., 2005. Mammalian prion protein suppresses bax-indued ell death inyeast. J. of Biol. Chem. 280, 17430-17434.Martin, R.H., 1976. Nonlinear Operators and Dierential Equations in Banah Spaes.Wiley-Intersiene Series of Texts, Monographs & Trats, New York 1976.Masel, J., Genoud, N., Aguzzi, A., 2005. EÆient inhibition of prion repliation by prp-f2suggests that the prion is a prpS oligomer. J. Mol. Biol. 345, 1243-1251.Masel, J., Jansen, V. A. A., Nowak, M. S., 1999. Quantifying the kineti parameters of prionrepliation. Biophys. Chem. 77, 139-152.Mobley, D. L., Cox, D. L., Singh, R. R., Kulkarni, R. V., Slepoy, A., 2003. Simulations ofoligomeri intermediates in prion diseases. Biophys. J. 85, 2213-2223.Nowak, M. A., Krakauer, D. C., Klug, A., May, R. M., 1998. Prion infetion dynamis.Integr. Biol. 1, 3-15.Oesh, B., Westaway, D., Walhli, M., MKinley, M. P., Kent, S. B. H., Aebersold, R., Barry,R. A., Tempst, P., Teplow, D. B., Hood, L. E., Prusiner, S. B., Weissmann, C., 1985. Aellular gene enodes srapie prp 27-30 protein. Cell. 40, 735-746.Pan, K. M., Baldwin, M., Nguyen, J. , Gasset, M., Serban, A., Groth, D., Il Melhorn,Huang, Z., Fletterik, R. J., Cohen, F. E., Prusiner, S. B., 1993. Conversion of -helies21
into -sheets features in the formation of the srapie prion proteins. Pro. Natl. Aad. Si.USA. 90, 10962-10966.Poshel, N. Brilliantov, V., Frommel, C., 2003. Kinetis of prion growth. Biophys. J. 85,3460-3474.Prusiner, S. B. 1986. Prions. Si. Am. 4, 50-59.Prusiner, S. B. 1991. Moleular biology of prion diseases. Siene. 252, 1515-1522.Prusiner, S. B. 1998. Prions. Pro. Natl. Aad. Si. USA. 95, 13363-13383.Prusiner, S. B., Groth, D. F., Bolton, D. C., Kent, S. B., Hood, L. E., 1984. Puriationand strutural studies of a major srapie prion protein. Cell. 38, 127-134.Prusiner, S. B., MKinley, M. P., Groth, D. F., Bowman, K. A., Mok, N. I., Cohran, S.P., Masiarz, F. R., 1981. Srapie agent ontains a hydrophobi protein. Pro. Natl. Aad.Si. USA. 78, 6675-6679.Pruss, J., Pujo-Menjouet, L., Webb, G. F., and Zaher, R., 2006. Analysis of a model forthe dynamis of prions. Disr. Cont. Dyn. Sys. -Ser. B. 6 (1), 215-225.Rouou, X., Gains, M., Leblan,A. C., 2004. Neuroprotetive funtions of prion protein. J.of Neurosiene Researh. 75:153-161.Rouou, X., Q. Guo, Y. Zhang, C. G. Goodyer, A. Leblan. 2003. Cytosoli prion protein is22
not toxi and protets against bax-mediated ell death in human primary neurons. J. Biol.Chem. 278:40877-40881.Rubenstein, R., P. A. Merz, R. J. Kassak, C. L. Salii, M. C. Papini, R. I. Carp, R. H.Kimberlin. 1991. Srapie-infeted spleens: analysis of infetivity, srapie-assoiated brils,and protease-resistant proteins. J. Infet. Dis. 164:29-35.Sheibel, T., A. S. Kowal, J. D. Bloom, S. L. Lindquist. 2001. Bidiretional amyloid bergrowth for a yeast prion determinant. Curr. Biol. 11: 366-369.Simonett, G. and Walker, C. On the solvability of a mathematial model for prion prolifer-ation. In press.Slepoy, A., R. V. Kulkarni, R. R. P. Singh, F. Pazmandi, D. L. Cox. 2001. On the statistialmehanis of prion proteins. Phys. Rev. Lett. 87:8101-8104.Wille, H., M. D. Mihelitsh, V. Guenebaut, S. Supattapone, A. Serban, F. E. Cohen, D.A. Agard, S. B. Prusiner. 2002. Strutural studies of the srapie prion protein by eletronrystallography. Pro. Natl. Aad. Si. USA. 99:3563-3568.
23
Table 1: Model parameters and variables denitions and units. The parameter values weretaken from Masel et al (Masel et al., 1999). SAF=sq means Srapie-Assoiated Fibrils persquare unit and is explained in detail by Rubenstein et al. in (Rubenstein et al., 1991).Parameter/Variable Denition Value Unitt time - daysx length of a PrPS polymer - -x0 minimum polymer length 6 -u(x; t) density of polymer lengths - SAF=sqU(t) total number of PrPS polymers - SAF=sqV (t) total number of PrPC monomers - -P (t) total number of PrPS monomers in polymers - - degradation rate of monomers 5 day 1 degradation rate of polymers .04 day 1 rate of splitting of polymers to monomers .0001 (SAF=sq) 1 day 1 soure of monomers 4; 400 day 1 onversion rate of monomers to polymers .3 (SAF=sq) 1 day 1(x; y) probability that a polymer of length ysplits to lengths x and y   x - -
24
Figure 1: Left: nuleated polymerization mehanism with minimum nuleation size n = 6.Right: Kineti model of the prion aggregate growth model based on Fig. 2 of Nowak et al.(Nowak et al., 1998)Figure 2: Evolution of the polymer density distribution u(x; t). For the graph on the leftrepresenting the early stage of the proliferation, the mean length of the polymers inreases,but then dereases with time. The graph in the right shows the stabilization of the poly-mer population as u(x; t) onverges to the disease steady state. The parameters used arepresented in Table 1. The simulations assume an initial PrPC population V0 = 880 and aninitial PrPS population u(y; 0) given by .000002 times a Gaussian distribution with mean.15 and standard deviation .03.
Figure 3: Evolution of the mean length P (t)=U(t) of the polymer as a funtion of the daysafter inoulation. The length of an average polymer inreases fast initially and then slowlydereases due to the depletion of the PrPC monomer population. The parameters used arepresented in Table 1. The simulations assume an initial PrPC population V0 = 880 and aninitial PrPS population u(y; 0) given by .000002 times a Gaussian distribution with mean.15 and standard deviation .03.
25
Figure 4: Top Figure: Inubation times in days for inoulum doses U(0) diluted throughnine orders of magnitude. All the points are linearly dependent on the log sale. Bottompanel: graphs of the number of brils U(t) (in SAF=sq) for the nine inoulum doses. Thehorizontal line orresponds to the onset of symptoms. The parameters are taken from Table1.Figure 5: Left panel: onvergene of V (t), U(t) and P (t) to the steady states V , U andP , with the parameters taken from Table 1. Right panel: srapie-assoiated brils (SAF)measurements at various times after intraerebral injetion of the 139A srapie strain intoCompton white mie (points). The solution U(t) of (8) is shown with parameters taken fromTable 1, and the experimental data ome from Rubenstein et al. (Rubenstein et al., 1991).The arrow indiates the time of onset of linial disease.
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